| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA2087523
Max Phase: Preclinical
Molecular Formula: C22H24FN5O2
Molecular Weight: 409.47
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CC(=O)NC(C)(C)c1nnc2cc(-c3cc(C(=O)NC4CC4)cc(F)c3C)ccn12
Standard InChI: InChI=1S/C22H24FN5O2/c1-12-17(9-15(10-18(12)23)20(30)24-16-5-6-16)14-7-8-28-19(11-14)26-27-21(28)22(3,4)25-13(2)29/h7-11,16H,5-6H2,1-4H3,(H,24,30)(H,25,29)
Standard InChI Key: NSDUXNLLUZMQCM-UHFFFAOYSA-N
Associated Targets(Human)
MAP kinase p38 delta 2605 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 409.47 | Molecular Weight (Monoisotopic): 409.1914 | AlogP: 3.11 | #Rotatable Bonds: 5 |
| Polar Surface Area: 88.39 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 12.22 | CX Basic pKa: 1.45 | CX LogP: 1.66 | CX LogD: 1.66 |
| Aromatic Rings: 3 | Heavy Atoms: 30 | QED Weighted: 0.68 | Np Likeness Score: -1.25 |
References
| 1. Aiguadé J, Balagué C, Carranco I, Caturla F, Domínguez M, Eastwood P, Esteve C, González J, Lumeras W, Orellana A, Preciado S, Roca R, Vidal L, Vidal B.. (2012) Novel triazolopyridylbenzamides as potent and selective p38α inhibitors., 22 (10): [PMID:22521646] [10.1016/j.bmcl.2012.03.099] |
Source
Source(1):